Altimmune

Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Altimmune reports positive trial results and financial stability in Q4

Altimmune's Q4 2022 performance showcased positive trial results for pemvidutide, despite financial challenges from negligible revenue.
The company's strengths lie in promising drug outcomes, strong cash reserves, and differentiated trial approaches.
Challenges include revenue generation, financial pressures, regulatory discussions, and dosing decisions for NASH treatment.
Opportunities exist in attracting investors, showcasing broader drug impact, enhancing prescribing flexibility, and demonstrating drug efficacy.

Altimmune reports strong Q1 performance with promising NASH and obesity results

Altimmune's Q1 2023 performance showcased strong cash reserves, increased R&D investment, and promising results for pemvidutide in NASH and obesity.
The company's focus on Phase 3 readiness, potential partnerships, and innovative antiviral combinations positions it well for future growth and development.
Challenges with trial discontinuation rates and pending data from the Boingo trial require attention, but Altimmune's strengths and opportunities offer a positive outlook.

Altimmune reports promising Q2 results, eyes HepTcell program advancement

Altimmune's Q2 performance reflects financial stability and progress in clinical development.
Strengths lie in promising trial data, strong financial position, and strategic clinical approach.
Challenges include addressing trial effectiveness, clarifying criteria, and monitoring potential effects.
Opportunities exist in liver fat reduction, HepTcell development, and broad immune response selection.

Altimmune reports positive trial results and financial stability in Q3

Altimmune's Q3 2023 performance reflects strong financial position and ongoing research efforts.
Pemvidutide and HepTcell trials show promise in treating obesity, NASH, and HBV.
Analyst interest and positive trial results indicate growth potential for Altimmune.
Focus on innovation and collaboration key to navigating challenges and seizing opportunities.

Altimmune reports promising trial results and seeks strategic partnerships for growth

Altimmune's Q4 performance reflected significant R&D investment and positive trial outcomes.
Strengths lie in pemvidutide's efficacy on liver fat reduction, MRI analysis, and oral formulation progress.
Challenges include partnership agreements, financial losses, and Phase III trial initiation timing.
Opportunities exist in IND development, trial enrollment progress, and strategic partnerships for market growth.

Altimmune reports promising trial results and seeks strategic partnerships

Altimmune's Q1 2024 performance reflects increased R&D expenses leading to a net loss, but the company maintains a strong cash position for future endeavors.
Pemvidutide's promising results in obesity trials position it as a potential best-in-class therapy, while ongoing studies aim to differentiate its use in treating liver conditions.
Despite challenges in partnership and regulatory discussions, Altimmune's compound shows strengths in tolerability and potential for expansion into new indications.

Altimmune reports strong Q3 performance, poised for growth opportunities

Altimmune's Q3 performance reflects financial strength and progress in key trials, positioning the company for future success.
While challenges such as FDA alignment and funding exist, strategic partnerships and additional indications present growth opportunities.
Investor interest remains high, supported by positive trial results and management's strategic focus on advancing the pipeline.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Altimmune, Inc. (ALT) delivered earnings and revenue surprises of 6.67% and 99.54%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Altimmune, Inc. (ALT) Reports Q2 Loss, Misses Revenue Estimates

Amylyx Pharmaceuticals

Arcutis Biotherapeutics

Axsome Therapeutics

bluebird bio

Heron Therapeutics

Intercept Pharma

These biotech stocks could be good buys due for a few reasons, including great R&D pipelines and treatments with promising market potential. The post 7 Biotech Stocks to Buy for Q3 appeared first on InvestorPlace.

7 Biotech Stocks to Buy for Q3

Does Altimmune, Inc. (ALT) have what it takes to be a top stock pick for momentum investors? Let's find out.

Here's Why Altimmune, Inc. (ALT) is a Great Momentum Stock to Buy

Here is how Altimmune, Inc. (ALT) and argenex (ARGX) have performed compared to their sector so far this year.

Is Altimmune (ALT) Stock Outpacing Its Medical Peers This Year?

Here is how Altimmune, Inc. (ALT) and Chinook Therapeutics (KDNY) have performed compared to their sector so far this year.

Is Altimmune (ALT) Outperforming Other Medical Stocks This Year?

Results from phase 1b NAFLD study using pemvidutide are to be released 2nd half of 2022;Q3 of 2022 will be 12-week data and Q4 of 2022 will be 24-week data. It is estimated that the global NASH market could be worth $20 billion by 2027.

Altimmune: Several Catalysts In 2 Large Market Indications This Year

Presentation to be highlighted in the Best of International Liver Congress Presentation to be highlighted in the Best of International Liver Congress

Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at Upcoming EASL International Liver Congress™ on June 25, 2022

Here is how Altimmune, Inc. (ALT) and Sensus Healthcare, Inc. (SRTS) have performed compared to their sector so far this year.

Has Altimmune (ALT) Outpaced Other Medical Stocks This Year?

The mean of analysts' price targets for Altimmune, Inc. (ALT) points to a 352.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Think Altimmune, Inc. (ALT) Could Surge 352%: Read This Before Placing a Bet

GAITHERSBURG, Md., May 31, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Samuel Klein, William H. Danforth Professor of Medicine and Nutritional Science Director, Washington University School of Medicine, will deliver an oral presentation at the 82nd American Diabetes Association (ADA) Scientific Sessions, to be held in New Orleans, LA on June 3-7, 2022. Dr. Klein will present the results of Altimmune's recently completed Phase 1, first-in-human clinical trial of pemvidutide, an investigational GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and NASH.

Altimmune to Present Pemvidutide Clinical Data at Upcoming American Diabetes Association Scientific Sessions June 6, 2022

The average of price targets set by Wall Street analysts indicates a potential upside of 425.9% in Altimmune, Inc. (ALT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts See a 426% Upside in Altimmune, Inc. (ALT): Can the Stock Really Move This High?

GAITHERSBURG, Md., May 20, 2022 (GLOBE NEWSWIRE) --  Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Scott Harris, Chief Medical Officer at Altimmune, will give an oral presentation at the 5th Global NASH Congress on May 26-27, 2022, in London, UK. His presentation will provide an overview of pemvidutide, the Company's novel, investigational GLP-1/glucagon dual receptor agonist under development for the treatment of obesity and NASH. Dr. Harris will also moderate a panel discussion on clinical endpoints in NASH trials.

Altimmune to Present Pemvidutide Clinical Data at Upcoming Global NASH Congress May 27, 2022

GAITHERSBURG, Md., May 16, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company's management team will participate at the following investor conferences in May 2022:

Altimmune to Present at Upcoming Investor Conferences

Altimmune, Inc. (NASDAQ:ALT ) Q1 2022 Earnings Conference Call May 12, 2022 8:30 AM ET Company Participants Vipin K. Garg – President and Chief Executive Officer Richard Eisenstadt – Chief Financial Officer Scot Roberts – Chief Scientific Officer Scott M.

Altimmune, Inc. (ALT) CEO Vipin K. Garg on Q1 2022 Results - Earnings Call Transcript

Altimmune, Inc. (ALT) delivered earnings and revenue surprises of 22.81% and 98.45%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Altimmune, Inc. (ALT) Reports Q1 Loss, Misses Revenue Estimates

The Company also announces completion of enrollment in 12-week, Phase 1b trial of pemvidutide in subjects with non-alcoholic fatty liver disease (NAFLD) The Company also announces completion of enrollment in 12-week, Phase 1b trial of pemvidutide in subjects with non-alcoholic fatty liver disease (NAFLD)

Altimmune Announces Initiation of 48-week Phase 2 MOMENTUM Trial of Pemvidutide in Obesity

Altimmune, Inc. (ALT) CEO Vipin Garg on Q4 2021 Results - Earnings Call Transcript

Altimmune, Inc. (ALT) delivered earnings and revenue surprises of 23.44% and 2,145.21%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Altimmune, Inc. (ALT) Reports Q4 Loss, Tops Revenue Estimates

Data readouts from multiple clinical trials expected during the next 6 to 12 months

Altimmune Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Corporate Update

GAITHERSBURG, Md., March 08, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its fourth quarter and full year 2021 financial results on Tuesday, March 15, 2022.

Altimmune to Report Fourth Quarter and Full Year 2021 Financial Results on March 15, 2022

Altimmune, Inc. (ALT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Altimmune, Inc. (ALT) to Report a Decline in Earnings: What to Look Out for

The FDA has cleared Altimmune Inc's ALT Investigational New Drug (IND) application for its Phase 2 trial of pemvidutide for obesity.  [ALERT] Nic Chahine shares his Bear Market Beating options trading strategy.

Altimmune's Mid-Stage Pemvidutide Study Cleared By FDA For Obesity

Enrollment in 48-week Phase 2 clinical trial expected to begin in Q1 2022 Enrollment in 48-week Phase 2 clinical trial expected to begin in Q1 2022

Altimmune Announces FDA Clearance of Pemvidutide (ALT-801) IND for Obesity

GAITHERSBURG, Md., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Scott Harris, Chief Medical Officer at Altimmune, will give an oral and a poster presentation on pemvidutide, the Company's novel, investigational GLP-1/Glucagon dual receptor agonist under development for the treatment of obesity and non-alcoholic steatohepatitis (NASH), the most severe form of non-alcoholic fatty liver disease (NAFLD). The presentations will take place at the NASH-TAG Conference, which is being held January 6-8, 2022, in Park City, Utah. Details for the oral presentation are as follows:

Altimmune to Present Pemvidutide Clinical Data at Upcoming NASH-TAG Conference January 8, 2022

Altimmune is changing its focus from infectious diseases towards metabolic and liver diseases. The company is leaning on Pemvidutide for obesity, NAFLD, and NASH. So far, the dual GLP-1/glucagon receptor agonist has produced impressive results in addressing metabolic dysfunction, which evolves into chronic diseases and comorbidity.

News for Altimmune Stock (ALT)